5 terminated. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 5 |
| Phase 2 | 3 | Terminated 3 |
Follow Recurrent B Acute Lymphoblastic Leukemia: new trials by email Literature Review of Recurrent B Acute Lymphoblastic Leukemia trials Research Report on Recurrent B Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| CD19-Specific T Cells Post AlloSCT Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-06-26 | 2021-06-02 |
| Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 53 | 2019-04-03 | 2026-05-13 |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2018-08-24 | 2025-12-12 |
| huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, Cyclophosphamide, Fludarabine - Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 55 | 2017-11-03 | 2024-04-10 |
Burkitt Lymphoma (5) · Lymphoma, Large B-Cell, Diffuse (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1)
DNA Virus Infections (5) · Epstein-Barr Virus Infections (5) · Hemic and Lymphatic Diseases (5) · Herpesviridae Infections (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Infections (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Tumor Virus Infections (5) · Virus Diseases (5) · Hematologic Diseases (4)
Cyclophosphamide (4) · CT-P10 (2) · Calcium Dobesilate (2) · Cytarabine (2) · Dexamethasone (2) · Methotrexate (2) · Prednisone (2) · Rituximab (2) · Vincristine (2) · auricularum (2) · deltacortene (2) · dexamethasone 21-phosphate (2) · dexamethasone acetate (2) · fludarabine (2) · merphos (2)
M.D. Anderson Cancer Center (4) · Fred Hutchinson Cancer Center (1)
United States (5)
Elias Jabbour (1) · Jordan Gauthier (1) · Nicholas Short, MD (1) · Nitin Jain (1) · Partow Kebriaei (1)
PMID 34515338, PMID 35622074, PMID 38207208, PMID 38324336, PMID 39820359